Blog Posts

Ashish Manne: The Potential of Cell-Free DNA Methylation Sequencing in Pancreatic Ductal Adenocarcinoma

Ashish Manne/X

May 28, 2025, 10:09

Ashish Manne: The Potential of Cell-Free DNA Methylation Sequencing in Pancreatic Ductal Adenocarcinoma

Ashish Manne, GI Medical Oncologist and Associate Professor at Ohio State University Comprehensive Cancer Center, shared a post on LinkedIn:

“Excited to share that we’ll be presenting our latest work at ASCO25!

Our poster highlights the potential of cell-free DNA methylation sequencing to better understand and predict treatment response in pancreatic ductal adenocarcinoma (PDA).

This work reflects our continued focus on decoding the biology of PDA — because in this disease, Biology Is King.

Looking forward to connecting with colleagues and collaborators in Chicago!”

Ashish Manne announced his team’s upcoming presentation at ASCO 2025, focusing on the use of cfDNA methylation sequencing to improve treatment response prediction in pancreatic ductal adenocarcinoma.

More posts on Adenocarcinoma on OncoDaily.

Adenocarcinoma ASCO25 Ashish Manne cancer Cell-Free DNA Methylation Sequencing Chicago fight against cancer Global fight against cancer James Cancer Hospital Ohio State University Comprehensive Cancer Center OncoDaily Oncology pancreatic ductal adenocarcinoma

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth